GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 69% increase in gross profit and a 14% rise in gross margin. The company has a robust cash position of $850 million, excluding a pending investment from Samsung. Despite some uncertainties, such as the impact of a $150 promotion, the company's strategic partnerships and growth in test volumes indicate a positive outlook. The updated FDA timeline and improved cost efficiencies further support a positive sentiment, suggesting a likely stock price increase over the next two weeks.
Key Financial Performance
Revenue for Q3 2025 $36.2 million, up $7.5 million or 26% compared to Q3 2024. Screening revenue was $32.8 million, up 29% year-over-year. U.S. Galleri revenue was $32.6 million, up 28% compared to Q3 2024. The increase was driven by higher demand for the Galleri test.
Net Loss for Q3 2025 $89 million, an improvement of 29% compared to Q3 2024. The improvement was due to cost management and operational efficiencies.
Non-GAAP Adjusted Gross Profit for Q3 2025 $20 million, an increase of $8.2 million or 69% compared to Q3 2024. This was driven by improvements in variable costs on the updated Galleri platform and increased sample volume.
Non-GAAP Adjusted Gross Margin for Q3 2025 55%, up from 41% in Q3 2024. The improvement was due to better lab efficiency and reduced fixed costs per sample.
Cash and Investment Position at the end of Q3 2025 $547.1 million, with an additional $325 million from a private placement in October, totaling approximately $850 million. This excludes a pending $110 million investment from Samsung.
Cost of Screening Revenue Decreased due to lower variable costs of Galleri testing on the automated platform, partially offset by a decrease in ASP and higher sample reprocessing costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Galleri test: Galleri volumes and revenue grew by 39% and 29% respectively in Q3 2025. Approximately 420,000 Galleri commercial tests have been sold by over 16,000 healthcare providers since launch. Galleri was introduced commercially in Canada in partnership with Medcan, and a strategic collaboration with Samsung was announced to bring Galleri to South Korea and potentially other Asian markets.
Market expansion: Strategic collaboration with Samsung to commercialize Galleri in South Korea and potentially other Asian markets, including Japan and Singapore. Galleri was also introduced in Canada in partnership with Medcan.
Operational efficiencies: Non-GAAP adjusted gross margin improved to 55% in Q3 2025 from 41% in Q3 2024, driven by lower variable costs and increased lab efficiency. Cash burn guidance for 2025 was reduced to no more than $290 million, representing a 50% decrease compared to 2024.
Strategic shifts: Completed a $325 million private placement to strengthen the balance sheet. Samsung agreed to make a $110 million equity investment in GRAIL, subject to closing conditions. Focus remains on seeking FDA approval for Galleri and pursuing broad reimbursement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Challenges: The company is seeking FDA approval for Galleri, which is a critical milestone for broad access and reimbursement. Delays or failure in obtaining regulatory approval could significantly impact the company's strategic objectives and market expansion.
Reimbursement and Market Access: Broad reimbursement for Galleri is a strategic priority. Challenges in achieving reimbursement could limit the test's accessibility and adoption, impacting revenue growth.
Financial Sustainability: Although the company has reduced its cash burn and extended its runway into 2030, it still reported a net loss of $89 million for the quarter. Sustained losses could pose financial risks if revenue growth does not meet expectations.
Operational Costs: While variable costs have decreased due to automation, there are still higher sample reprocessing costs and seasonal fluctuations in revenue, which could affect profitability.
International Expansion Risks: The company is expanding into international markets like South Korea, Japan, Singapore, and Canada. These expansions are subject to execution risks, including regulatory approvals, market acceptance, and operational challenges.
Clinical Validation and Data Reliability: The company relies heavily on clinical studies like PATHFINDER 2 and NHS Galleri for regulatory submissions and market credibility. Any issues with data reliability or study outcomes could hinder regulatory approval and market adoption.
Competitive Pressures: Galleri is currently the only MCED test with demonstrated performance, but the market could face competitive pressures from new entrants or alternative technologies, which could impact market share.
Economic and Market Conditions: Economic uncertainties and market conditions could affect healthcare spending and the adoption of new technologies like Galleri, impacting revenue and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company has refined its full-year 2025 U.S. Galleri revenue growth guidance to the middle of the previously guided range of 20% to 30%.
Cash Burn Guidance: The company has updated its cash burn guidance for the full year 2025 to no more than $290 million, down from the previous guidance of no more than $310 million.
Cash Runway: The company expects its cash runway to extend into 2030, enabling it to achieve major planned clinical and regulatory milestones.
FDA Approval and Reimbursement: The company is prioritizing seeking FDA approval for Galleri and pursuing broad reimbursement. Key milestones include the completion of the modular PMA submission to the FDA in 2026.
NHS Galleri Study: The full clinical utility results from the 140,000-participant NHS Galleri study are expected to be available mid-2026. This data will be reviewed by the NHS to determine Galleri's potential deployment within the U.K. population.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:The FDA timeline is moved to Q1 instead of the first half of 2026. What changed?
A:The timeline adjustment reflects increased certainty in the range of delivery as progress has been made. Previously, the company had been stating 'first half' of 2026, but now they are confident enough to specify Q1.
Q:You're currently running a promotion offering $150 off Galleri for patients getting tested from October to year-end. What incentivized this promotion? How has demand elasticity responded? Are you piloting a reduction to $800 moving forward, and could this impact ASPs?
A:The promotion reflects the company's analysis of price elasticity, showing significant demand response to price changes. The timing aligns with the end of the year to maximize impact. The promotion has driven growth in prescribing breadth and depth, supported by integrations with companies like Quest and Athena. Repeat testing has also contributed to growth. However, no specific mention was made about piloting a permanent price reduction to $800 or its impact on ASPs.
Q:How do you plan to use the additional $400 million from the Samsung investment, and how does the commercial strategy change in light of competition?
A:The additional capital provides flexibility for commercial investments and scaling the test footprint. The company is focusing on fortifying areas to expand its market presence. They also emphasized momentum in customer engagement, supported by recent data presentations like PATHFINDER 2.
Q:Hims & Hers has invested in the company. Does this mean GRAIL will take a direct-to-consumer approach to Galleri?
A:The company remains committed to the PMA pathway and has no immediate plans to shift to a direct-to-consumer approach. However, they recognize the importance of digital health channels for broader access and may explore such channels in the future without compromising their PMA focus.
Q:Regarding NHS England, what prompted the decision in May 2024 to not justify a large-scale pilot? Has anyone besides GRAIL and the NHS evaluation team seen the year 1 NHS Galleri data? When will this data be released?
A:NHS England required exceptional data to accelerate implementation, focusing on metrics like PPV. The data from year 1 was not exceptional enough to justify acceleration. Only the NHS evaluation team has seen the data, and it will not be publicly available until the final study results are released in mid-2026.
Q:What is driving the 39% year-over-year volume growth, and will international markets contribute next year?
A:Volume growth is driven by increased provider pull-through and domestic momentum. International volumes are currently minimal, but the company is exploring opportunities, including through partnerships like Samsung. It is too early to predict international contributions for next year.
Q:Can you elaborate on the SIMPLIFY study and its implications for cancer detection?
A:The study highlights the challenge of nonspecific symptoms leading to missed cancer diagnoses during follow-ups. The CSO prediction could have guided investigations more effectively, potentially improving diagnostic outcomes. Real-world data from centers like Mayo and Dana-Farber show high PPVs, reinforcing the value of the CSO in guiding diagnostic workups.
Q:Cost of screening revenue declined sequentially and year-over-year on a per-test basis. How is this being achieved, and what is the trajectory?
A:The decline reflects the company's high-throughput platform and fixed-cost leverage. Improved variable costs, such as processing more samples per flow cell, also contribute. The company is focused on driving volume to maximize the efficiency of its infrastructure and improve margins.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether the $150 promotion would lead to a permanent price reduction to $800 or its impact on ASPs. Additionally, they did not provide clarity on the specific commercial strategy changes in response to competition, only emphasizing flexibility and momentum.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CSO prediction
Canada Medcan
Canada test
Cancer Conference
Cancer Registry
Chief Scientific
Conference EDCC
Detection Cancer
EDCC financing
ESMO
Harpal
Officer President
PPV population
SIMPLIFY study
Scientific Officer
addition
cash investment
closing condition
collaboration Samsung
diagnosis
finding
group
investment GRAIL
lab efficiency
partner
placement
procedure
program
resolution
result study
round NHS
sample volume
study event
symptom
update
validation
volume quarter
GRAL Transcript
GRAIL, Inc. (GRAL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call reveals strong financial performance with a 25% YoY revenue increase and improved gross margins. The company turned profitable with a $20 million net income, indicating effective cost control. Although forward-looking statements highlight risks, the financial metrics are robust, suggesting a positive outlook. The lack of discussion on strategic initiatives and shareholder returns slightly tempers the sentiment, but overall, the financial improvements and profitability provide a positive outlook for the stock price over the next two weeks.
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
Unknown2-19
The earnings call summary presents a mixed outlook. While there is a positive emphasis on product development and strategic partnerships, the Q&A reveals concerns about trial results and FDA approval. The NHS-Galleri study's missed endpoint and lack of significant Stage III and IV cancer reduction are worrying. However, the company's optimism about future milestones and financial health, along with potential international expansion, balances the sentiment. The lack of market cap data limits the prediction's precision, but overall, the sentiment is neutral due to these mixed signals.
GRAL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
